Perpetrators | Dosing regimens | Victims | Predicted ratiosa | Observed ratiosa | ||||
---|---|---|---|---|---|---|---|---|
AUC | Cmax | tPDE4ib | AUC | Cmax | tPDE4ib | |||
KET | ROF: Repeated-doses of 0.5 mg OD from days 1 to 11; KET: A single dose of 200 mg on day 11 | ROF | 1.43 | 1.07 | - | 1.34 | 1.06 | NR |
ROF N-oxide | 1.06 | 0.95 | 0.88 | 0.80 | ||||
ROF: Single-dose of 0.5 mg OD on days 1 and 11, respectively; KET: Repeated-doses of 200 mg BID from days 8 to 20 | ROF | 2.07 | 1.18 | 1.34 | 2.01 | 1.23 | 1.10 | |
ROF N-oxide | 1.33 | 0.96 | 1.09 | 0.62 | ||||
FLUV | ROF: Single-dose of 0.5 mg OD on day 15; FLU: Repeated-doses of 50 mg OD from days 8 to 21 | ROF | 2.29 | 1.16 | 1.62 | 2.56 | 1.12 | 1.59 |
ROF N-oxide | 1.66 | 0.84 | 1.52 | 0.80 | ||||
RIF | ROF: Single-dose of 0.5 mg OD on day 12; RIF: Repeated-doses of 600 mg OD from days 5 to 15 | ROF | 0.20 | 0.63 | 0.44 | 0.32 | 0.19 | 0.43 |
ROF N-oxide | 0.44 | 1.28 | 0.49 | 1.30 | ||||
ENO | ROF: Single-dose of 0.5 mg OD on days 1 and 12, respectively; ENO: Repeated-doses of 400 mg BID from days 2 to 19 | ROF | 1.22 | 1.19 | 1.21 | 1.58 | 1.20 | 1.25 |
ROF N-oxide | 1.02 | 1.12 | 1.20 | 0.86 | ||||
CIM | ROF: Single-dose of 0.5 mg OD on days 1 and 13, respectively; CIM: Repeated-doses of 400 mg BID from days 6 to 16 | ROF | 1.37 | 1.07 | 1.06 | 1.46 | 1.85 | 1.48 |
ROF N-oxide | 1.04 | 0.94 | 0.96 | 1.27 | ||||
ITR | Concomitantly used at repeated-doses of ITR 200 mg OD, FLU 150 mg OD, EFA 600 mg OD, respectively, and ROF 0.5 mg OD on day14 | ROF | 2.14 | 1.16 | 1.40 | NR | NR | |
ROF N-oxide | 1.22 | 0.70 | ||||||
FLU | ROF | 1.89 | 1.18 | 1.16 | ||||
ROF N-oxide | 1.12 | 0.92 | ||||||
EFA | ROF | 0.28 | 0.64 | 0.58 | ||||
ROF N-oxide | 0.60 | 1.16 |